Israeli HealthTech startup Lydus Medical scores $2.7M in funding to revolutionize surgical anastomosis with automated microsurgery

Microsurgical anastomosis is a term you probably never heard of. If it sounds like something complicated, that’s because it is. In biology, an anastomosis refers to connections between blood vessels or between other tubular structures such as loops of the intestine.

Microsurgical anastomosis is a type of microsurgery that’s necessary for many complex operations, including breast reconstruction, peripheral bypass surgeries, the creation of vascular access for hemodialysis, and more. The procedure is used in an estimated 7 million surgeries per year.

Enter Lydus Medical, a HaMerkaz, Israel-based HealthTech startup that is working on making surgical anastomosis quite a bit easier. The startup is taking an innovative approach to the surgical anastomosis, the connection of ultra-small blood and lymph vessels to one another with automated microsurgery. Lydus is part of a portfolio company of Sanara Ventures – a JV of Teva and Philips and an anastomosis technology provider.

Today, Lydus announced it has raised $2.7 million in Pre-Series A funding to support the company’s ability to accelerate FDA clearance while scaling product development and prepare for market entry.

The funding round was led by the strategic player, together with additional investors Mor Research, Technion, and Leon Recanati’s private equity investment company, with participation from Glenrock as well as additional investors.

Lydus Medical was founded in 2017 by Prof. Ad-El, Head of Plastic Surgery Dep, Dr. Mansour, Plastic surgery Dep. both at Belinson Hospital in Israel and Mr. Daas, engineer and serial inventor, responsible for hundreds of patents and Sanara Ventures, an investment platform which focuses on early-stage life science companies.

Jessica Weiss, CEO of Lydus Medical

“Anastomosis is one of the most complicated steps of surgery and the key to the success of many procedures, and it is still performed manually, making it time and labor-intense, requiring high surgeon dexterity and a very unique skill set very few surgeons worldwide possess. This reality often results in poor clinical outcomes,” said Jessica Weiss, the company’s CEO.

Weiss added: “Lydus technology delivers standardized, accurate anastomosis, significantly improving clinical results, shortening operation time and enabling successful microsurgery procedures even when a rare, highly skilled microsurgeon isn’t available.”

Lydus developed, the Vesseal, a unique surgical device that enables precise, symmetrical, and rapid connection of blood and lymph vessels of tiny diameters, ranging from 4.0 to 0.5mm, for complicated procedures, from breast reconstruction and lymphedema to bypass surgery and vascular access for hemodialysis. Lydus pipeline includes a diverse portfolio of products, all based on a patented invention.

“Lydus Medical, brings great innovation to the complex unmet need of surgical suturing, which includes more than 7 million surgeries a year across a variety of indications, reflecting a huge number of potential users of Lydus device,” said Assaf Barnea, Sanara Ventures, CEO and the Chairman of the company.